Janssen’s type 2 diabetes drug Vokanamet gets European Commission approval in EU
Janssen-Cilag International (Janssen) has received approval from the European Commission (EC) for use of Vokanamet in the European Union (EU) as a treatment for...
Alexion begins multinational registration trials of eculizumab to treat NMO and MG
US-based Alexion Pharmaceuticals has started a single, multinational, placebo-controlled trial designed to assess the safety and efficacy of eculizumab (Soliris) in patients with relapsing...
NICE recommends afatinib for treatment of lung cancer
The National Institute for Health and Care Excellence (NICE) in the UK has issued its final health technology appraisal recommending afatinib as a first-line...
Pfizer confirms £60bn bid interest in AstraZeneca
US-based drug maker Pfizer has confirmed that it has contacted AstraZeneca seeking to renew discussions over a possible £60bn takeover. The discussions are regarding...
Eli Lilly’s Cyramza becomes first FDA-approved gastric cancer drug
Eli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic...
Abbvie starts Phase III trial of lung cancer drug veliparib
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor 'veliparib...
Roche Signs Licensing Agreement with Sysmex Inostics GmbH for emPCR Patent Portfolio
Pleasanton, CA, USA, 21 February 2014 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a licensing agreement with Sysmex Inostics GmbH for its...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...